Promino Nutritional Sciences（93X）株式概要栄養補助食品会社であるプロミノ・ニュートリショナル・サイエンシズ社は、カナダと米国で栄養製品の開発に従事している。 詳細93X ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性2/6配当金0/6報酬過去5年間の収益は年間17.8%増加しました。 リスク分析過去1年間で株主の希薄化は大幅に進んだ マイナスの株主資本 意味のある時価総額がありません ( €6M )German市場と比較して、過去 3 か月間の株価の変動が非常に大きい+1 さらなるリスクすべてのリスクチェックを見る93X Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.0151.6k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-10m4m2016201920222025202620282031Revenue CA$550.8kEarnings CA$55.9kAdvancedSet Fair ValueView all narrativesPromino Nutritional Sciences Inc. 競合他社Brigit Biofarmaka TechnologiSymbol: IDX:OBATMarket cap: Rp165.6bDSwissSymbol: OTCPK:DQWSMarket cap: US$8.8mCalmer Co InternationalSymbol: ASX:CCOMarket cap: AU$7.0mLaboratorio Farmaceutico ErfoSymbol: BIT:ERFOMarket cap: €9.3m価格と性能株価の高値、安値、推移の概要Promino Nutritional Sciences過去の株価現在の株価CA$0.01552週高値CA$0.0452週安値CA$0.005ベータ1.521ヶ月の変化-8.82%3ヶ月変化-22.50%1年変化n/a3年間の変化-94.32%5年間の変化n/aIPOからの変化-99.05%最新ニュースReported Earnings • May 31First quarter 2026 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 1Q 2025)First quarter 2026 results: CA$0.002 loss per share (improved from CA$0.005 loss in 1Q 2025). Revenue: CA$160.7k (down 38% from 1Q 2025). Net loss: CA$409.4k (loss narrowed 24% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.お知らせ • May 22Promino Nutritional Sciences Inc. announced that it has received CAD 0.95931 million in fundingOn May 21, 2026, Promino Nutritional Sciences Inc. closed the transaction. The company issued 3,000,000 units at a price of CAD 0.03 per Unit for gross proceeds of CAD 90,000 in its final tranche. In aggregate, the Company issued 31,976,999 Units for gross proceeds of CAD 959,309.97 in its private placement. The Units are composed of one Share and one half of one Share purchase warrant, each whole warrant exercisable into one additional Share at a price of CAD 0.06 for one year from the date of issuance. All securities issued upon closing of the Final Tranche are subject to a four-month hold period in accordance with applicable securities laws.お知らせ • Apr 11Promino Nutritional Sciences Inc. Launches NCAA Division I Athlete Platform Through Multi-Sport Nil Partnership with Virginia Military InstitutePromino Nutritional Sciences Inc. announced a multi-sport Name, Image and Likeness ("NIL") partnership with eight NCAA Division I student-athletes at the Virginia Military Institute ("VMI"). This agreement marks the formal launch of the Promino NCAA Athlete Platform, a strategic initiative designed to provide collegiate athletes with the Company's NSF Certified for Sport® proprietary amino acid formulations. The partnership includes eight cadet-athletes across VMI's Division I programs, who will integrate the formulation into their training and recovery protocols. The Company intends to utilize this multi-sport program as a model for potential expansion into additional NCAA athletic programs, subject to future agreements. Promino's performance platform is engineered to support muscle protein synthesis and recovery through precise, low-calorie formulations. Unlike traditional protein formats that require lengthy digestion, Promino's proprietary ratio is designed for rapid absorption, delivering muscle-building support without "digestive drag" or excess calories. Its core product, Rejuvenate Muscle Health™, is a clinically researched proprietary amino acid formula designed to rebuild, restore, and rejuvenate muscle tissue. The Company also produces Promino™ - NSF Certified for Sport®.お知らせ • Mar 14Promino Nutritional Sciences Inc. announced that it expects to receive CAD 1.2 million in fundingPromino Nutritional Sciences Inc announced a non brokered private placement to issue 40,000,000 units of the Company ("Units") at a price of CAD 0.03 per Unit for gross proceeds of CAD 1,200,000 on March 13, 2026. Each Unit will consist of one common share and one half of one common share purchase warrant with each Warrant being exercisable to purchase one additional Share at a price of CAD 0.06 for twelve months from the date of issuance. The Company may pay finders' fees in connection with the Offering, as permitted by applicable securities laws and the rules of the Canadian Securities Exchange. The Offering is expected to close on or about April 15, 2026 and is subject to execution of subscription agreements by the placees and to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange. All securities issued in connection with the Offering will be subject to a four month and one day statutory resale restriction pursuant to applicable Canadian securities laws.お知らせ • Dec 19Promino Nutritional Sciences Inc. announced that it expects to receive CAD 1.5 million in fundingPromino Nutritional Sciences Inc announced a non-brokered private placement to issue 50,000,000 units at an issue price of CAD 0.02 for the proceeds of CAD 1,000,000 on December 18, 2025. The company may increase the size of the new offering by up to 25,000,000 additional units. Each unit will consist of one common share and one common share purchase warrant, with each warrant being exercisable to purchase one additional share at a price of CAD 0.06 for 12 months from the date of issuance. The new offering is expected to close on or about January 30, 2026, and is subject to conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange. All securities issued in connection with the new offering will be subject to a four-month-and-one-day statutory resale restriction pursuant to applicable Canadian securities laws. On the same day the company amended the terms of the transaction. The company will now issue 50,000,000 units at an issue price of CAD 0.03 for gross proceeds of CAD 1,500,000. All other offering terms remain unchanged.お知らせ • Dec 10Promino Nutritional Sciences Inc., Annual General Meeting, Feb 12, 2026Promino Nutritional Sciences Inc., Annual General Meeting, Feb 12, 2026.最新情報をもっと見るRecent updatesReported Earnings • May 31First quarter 2026 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 1Q 2025)First quarter 2026 results: CA$0.002 loss per share (improved from CA$0.005 loss in 1Q 2025). Revenue: CA$160.7k (down 38% from 1Q 2025). Net loss: CA$409.4k (loss narrowed 24% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.お知らせ • May 22Promino Nutritional Sciences Inc. announced that it has received CAD 0.95931 million in fundingOn May 21, 2026, Promino Nutritional Sciences Inc. closed the transaction. The company issued 3,000,000 units at a price of CAD 0.03 per Unit for gross proceeds of CAD 90,000 in its final tranche. In aggregate, the Company issued 31,976,999 Units for gross proceeds of CAD 959,309.97 in its private placement. The Units are composed of one Share and one half of one Share purchase warrant, each whole warrant exercisable into one additional Share at a price of CAD 0.06 for one year from the date of issuance. All securities issued upon closing of the Final Tranche are subject to a four-month hold period in accordance with applicable securities laws.お知らせ • Apr 11Promino Nutritional Sciences Inc. Launches NCAA Division I Athlete Platform Through Multi-Sport Nil Partnership with Virginia Military InstitutePromino Nutritional Sciences Inc. announced a multi-sport Name, Image and Likeness ("NIL") partnership with eight NCAA Division I student-athletes at the Virginia Military Institute ("VMI"). This agreement marks the formal launch of the Promino NCAA Athlete Platform, a strategic initiative designed to provide collegiate athletes with the Company's NSF Certified for Sport® proprietary amino acid formulations. The partnership includes eight cadet-athletes across VMI's Division I programs, who will integrate the formulation into their training and recovery protocols. The Company intends to utilize this multi-sport program as a model for potential expansion into additional NCAA athletic programs, subject to future agreements. Promino's performance platform is engineered to support muscle protein synthesis and recovery through precise, low-calorie formulations. Unlike traditional protein formats that require lengthy digestion, Promino's proprietary ratio is designed for rapid absorption, delivering muscle-building support without "digestive drag" or excess calories. Its core product, Rejuvenate Muscle Health™, is a clinically researched proprietary amino acid formula designed to rebuild, restore, and rejuvenate muscle tissue. The Company also produces Promino™ - NSF Certified for Sport®.お知らせ • Mar 14Promino Nutritional Sciences Inc. announced that it expects to receive CAD 1.2 million in fundingPromino Nutritional Sciences Inc announced a non brokered private placement to issue 40,000,000 units of the Company ("Units") at a price of CAD 0.03 per Unit for gross proceeds of CAD 1,200,000 on March 13, 2026. Each Unit will consist of one common share and one half of one common share purchase warrant with each Warrant being exercisable to purchase one additional Share at a price of CAD 0.06 for twelve months from the date of issuance. The Company may pay finders' fees in connection with the Offering, as permitted by applicable securities laws and the rules of the Canadian Securities Exchange. The Offering is expected to close on or about April 15, 2026 and is subject to execution of subscription agreements by the placees and to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange. All securities issued in connection with the Offering will be subject to a four month and one day statutory resale restriction pursuant to applicable Canadian securities laws.お知らせ • Dec 19Promino Nutritional Sciences Inc. announced that it expects to receive CAD 1.5 million in fundingPromino Nutritional Sciences Inc announced a non-brokered private placement to issue 50,000,000 units at an issue price of CAD 0.02 for the proceeds of CAD 1,000,000 on December 18, 2025. The company may increase the size of the new offering by up to 25,000,000 additional units. Each unit will consist of one common share and one common share purchase warrant, with each warrant being exercisable to purchase one additional share at a price of CAD 0.06 for 12 months from the date of issuance. The new offering is expected to close on or about January 30, 2026, and is subject to conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange. All securities issued in connection with the new offering will be subject to a four-month-and-one-day statutory resale restriction pursuant to applicable Canadian securities laws. On the same day the company amended the terms of the transaction. The company will now issue 50,000,000 units at an issue price of CAD 0.03 for gross proceeds of CAD 1,500,000. All other offering terms remain unchanged.お知らせ • Dec 10Promino Nutritional Sciences Inc., Annual General Meeting, Feb 12, 2026Promino Nutritional Sciences Inc., Annual General Meeting, Feb 12, 2026.お知らせ • Dec 09Promino Nutritional Sciences Inc. announced that it expects to receive CAD 1 million in fundingPromino Nutritional Sciences Inc. announced non-brokered private placement of 15% secured convertible debentures due December 3, 2028 for an aggregate principal amount of up to CAD 1,000,000 on December 9, 2025. The Company may increase the size of the Offering by up to an additional CAD 500,000 of Convertible Debentures for aggregate gross proceeds of up to CAD 1,500,000. Each Convertible Debenture will consist of a CAD 1,000 principal amount and be secured against company's present and after-acquired inventory. The Convertible Debentures will bear interest at a rate of 15% per annum, payable quarterly in, at the election of the company, cash or common shares of the Company at a conversion price of the greater of (i) CAD 0.05 and (ii) the five-day VWAP of the Shares prior to the interest payment date. The principal amount outstanding under the Convertible Debentures will be, at the election of the company, payable in cash or convertible into Shares at a conversion price of CAD 0.05 per Share on maturity three (3) years from the date of issuance (the "Maturity Date"). The company may also elect to repay the principal amount of the Convertible Debentures in cash, in whole or in part, at any time prior to the Maturity Date. The Convertible Debentures shall be convertible at the option of the holder, in whole or in part, and at any time prior to the Maturity Date, into Shares at a conversion price of CAD 0.05 per Share. The Offering is subject to the approval of the Canadian Securities Exchange ("CSE"). The Convertible Debentures and the Shares issuable upon conversion of the Convertible Debentures or any interest thereon will be subject to a four month and one day statutory resale restriction pursuant to applicable Canadian securities laws. The Offering is expected to close on or about January 30, 2026 and is subject to execution of subscription agreements by the placees and to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the CSE. The company also announces that it has granted 500,000 options to purchase Shares, with an exercise price of CAD 0.05 and maturity date of December 3, 2028, to a consultant of the Company. The securities issued under this grant are subject to a four month and one day statutory resale restriction pursuant to applicable Canadian securities laws.お知らせ • Sep 08+ 1 more updatePromino Nutritional Sciences Inc. Announces Management ChangesPromino Nutritional Sciences Inc. announced that Moira Ong has been appointed as Corporate Secretary and Vito Sanzone has been appointed as a Director of the Company. Mr. Sanzone is currently the CEO. Mr. Sanzone has 25 years of experience in the health, wellness and fitness industry and has had executive roles in three performance nutrition mergers and acquisitions worth a combined $1 billion. Ms. Ong has over 20 years' experience in financial reporting, compliance and audit. Ms. Ong has served as Vice President of Finance and Chief Financial Officer of private and publicly-listed entities since 2010 and assisted these companies with public listings processes, mergers and acquisitions. The Company also announces that Shaun Power has resigned as Corporate Secretary and Director. The Company wishes to thank Mr. Power for his contributions to the Company.お知らせ • Apr 04Promino Nutritional Sciences Inc. announced that it has received CAD 0.86405 million in fundingOn April 3, 2025, Promino Nutritional Sciences Inc closed the transaction. The company issued 10,881,000 Units at a price of CAD 0.05 per Unit for gross proceeds of CAD 544,050. The company paid cash finder's fees in the aggregate amount of CAD 35,073.50 and issued an aggregate of 701,470 non-transferable finder's unit warrants.お知らせ • Sep 18Promino Nutritional Sciences Inc. Begins Preclinical Trial to Demonstrate Effectiveness of Promino™ Patented IP for Retention of Muscle Mass in Cancer Patients Undergoing Aggressive Chemotherapy TreatmentPromino Nutritional Sciences Inc. has announced the commencement of the preclinical trial to demonstrate the effectiveness of the Promino™ patented IP for the retention of muscle mass in cancer patients undergoing aggressive chemotherapy treatment. The preclinical trial will be led by Dr. Patrick Gunning, who was appointed as special advisor to the Company on May 8, 2024 to conduct these trials. Results of the preclinical trials are expected in 10 weeks. If testing affirms the effectiveness of the patented IP in retaining muscle mass in chemotherapy patients, the Company will likely develop a specialized formulation specifically for marketing to the practitioner channel in North America.お知らせ • Sep 09Promino Nutritional Sciences Inc. Announces the Release of Results of A New Human Clinical TrialPromino Nutritional Sciences Inc. announced the release of results of a new human clinical trial led by Dr. Robert R. Wolfe, Phd. The trial found that a 3.6 gram serving of Rejuvenate Muscle ActivatorTM has the same effect on muscle protein synthesis as 40 grams of whey protein. The clinical trial measured protein equivalency between the patented essential amino acid blend underlying Rejuvenate Muscle ActivatorTM and ProminoTM versus traditional whey protein, long considered the leader in muscle health. The patented amino acid blend was found to be 11x more effective than whey protein isolate gram-for-gram. Research from Dr. Wolfe and his team at the University of Arkansas can be found here. Promino is the exclusive licensor of the patent for the global mass consumer and sports nutrition markets. The patent is the result of over 20 years of research, over 25 clinical trials and funding of over USD 20 million. The Company recently re-launched Rejuvenate Muscle ActivatorTM (3.6 gram serving), marketed to the mass active nutrition and wellness category, and ProminoTM- NSF Certified for Sport® (11 gram serving), designed for professional and collegiate athletes and sports nutrition channels. The results of the clinical trial demonstrate the commercial value of the patented blend by supporting its efficiency, cost effectiveness and clean formula.Reported Earnings • Sep 05Second quarter 2024 earnings released: CA$0.042 loss per share (vs CA$0.028 loss in 2Q 2023)Second quarter 2024 results: CA$0.042 loss per share (further deteriorated from CA$0.028 loss in 2Q 2023). Revenue: CA$11.6k (down 90% from 2Q 2023). Net loss: CA$2.72m (loss widened 161% from 2Q 2023).お知らせ • Jul 10Promino Nutritional Sciences Inc. announced that it has received CAD 1.749001 million in fundingOn July 9, 2024, Promino Nutritional Sciences Inc. closed the transaction. The company issued 166,666 Units at a price of CAD 0.18 per Unit for gross proceeds of CAD 29,999.88 in second and final tranche. Each Unit comprised of one common share and one common share purchase warrant. Each warrant is exercisable to acquire one common share of the Company at a price of CAD 0.30 per share for a period of 24 months from the date of issuance. Together with the first tranche, the Company has issued an aggregate of 9,716,671 Units for gross proceeds of CAD 1,749,000.78. All securities issued in connection with the second tranche are subject to a hold period of four months and one day pursuant to applicable securities laws. The Company did not pay any finder’s fees, in cash nor securities, in connection with the second tranche.お知らせ • May 15Promino Nutritional Sciences Inc., Annual General Meeting, Jul 09, 2024Promino Nutritional Sciences Inc., Annual General Meeting, Jul 09, 2024. Location: british columbia, vancouver CanadaReported Earnings • May 09Full year 2023 earnings released: CA$0.15 loss per share (vs CA$0.29 loss in FY 2022)Full year 2023 results: CA$0.15 loss per share (improved from CA$0.29 loss in FY 2022). Revenue: CA$478.2k (down 88% from FY 2022). Net loss: CA$5.81m (loss narrowed 44% from FY 2022).お知らせ • Apr 30Promino Nutritional Sciences Inc. (CNSX:MUSL) entered into a binding letter of intent to acquire Helios Helium Corp. for CAD 5.84 million.Promino Nutritional Sciences Inc. (CNSX:MUSL) entered into a binding letter of intent to acquire Helios Helium Corp. for CAD 5.84 million on April 29, 2024. Total share consideration is expected to be approximately 36.5 million Promino common shares. Pursuant to the LOI, Helios will spin out its helium property and sundry assets into a new entity, such that Helios’ assets will only be comprised of cash and certain marketable securities. Thereafter, each shareholder of Helios will receive one common share of the Company in exchange for each common share of Helios held. Completion of the Transaction will be subject to the satisfaction or waiver of customary conditions, including the satisfactory completion of due diligence, the entering into of a definitive agreement for the proposed Transaction and the receipt of all necessary approvals and consents, including regulatory, corporate, court and shareholder approval, if applicable.New Risk • Feb 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 52% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (37% average weekly change). Negative equity (-CA$7.7m). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (52% increase in shares outstanding). Revenue is less than US$1m (CA$265k revenue, or US$197k). Minor Risk Market cap is less than US$100m (€10.1m market cap, or US$10.8m).お知らせ • Feb 07Promino Nutritional Sciences Inc. announced that it has received CAD 2.208075 million in fundingOn February 6, 2024, Promino Nutritional Sciences Inc. closed the transaction. The company issued 44,161,500 units at an issue price of CAD 0.05 for the gross proceeds of up to CAD 2,208,075. Each unit will be comprised of one common share of the company and one-half of one common share purchase warrant, with each whole warrant exercisable to acquire one common share of the company at a price of CAD 0.10 per share for a period of 24 months from the date of issuance. All securities issued in connection with the offering will be subject to a statutory hold period of four months and one day. The company paid cash finder's fees in the aggregate amount of CAD 113,570 and issued2,271,400 finder's warrants to certain finders who introduced purchasers to the Company. Each finder's warrant is exercisable to acquire one common share of the Company at a price of CAD 0.10 per share for a period of 24 months from the date of issuance. The transaction included participation from an insider of the Company for 1,000,000 Units.New Risk • Nov 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$2.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.1m free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Negative equity (-CA$7.7m). Earnings have declined by 18% per year over the past 5 years. Revenue is less than US$1m (CA$265k revenue, or US$195k). Market cap is less than US$10m (€3.22m market cap, or US$3.51m). Minor Risk Shareholders have been diluted in the past year (6.4% increase in shares outstanding).お知らせ • Oct 12Element Nutritional Sciences Inc. Appoints Adam Berk as AdvisorElement Nutritional Sciences Inc. announced the appointment of Adam Berk as an independent Advisor to aid the Company to accelerate commercialization of its RejuvenateTM and PROMINO TM brands. Most recently, Mr. Berk was President of a renowned nutraceutical and vitamin company where he aided in acquisitions and helped grow the brand. Mr. Berk's most notable experience also includes over five years as Chairman and CEO of Stem Holdings Inc., three years as CEO of HYD for Men, and Co-CEO of Osmio, LLC.お知らせ • Sep 27+ 1 more updateElement Nutritional Sciences Inc. Announces Executive ChangesElement Nutritional Sciences Inc. named veteran health and fitness executive Vito Sanzone as Chief Executive Officer, replacing founder Stuart Lowther who resigned as Chief Executive Officer to address personal matters. The change is effective immediately. Mr. Sanzone previously served Element as Chief Marketing Officer and has helped drive the creation of Element's new product portfolio. He has been part of over USD 1 billion in mergers and acquisitions in the health and active nutrition industry since 2016. Prior to Element, Mr. Sanzone was Chief Executive Officer of Complete Nutrition, Inc, where he spearheaded the transition to a major digital presence. As President of Maximum Human Performance, he repositioned the brand for sale in 2017. He also served as a key executive of Iovate Health Sciences in Oakville, Ontario from 2007 to 2016.New Risk • Aug 27New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-CA$5.6m). Earnings have declined by 24% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Revenue is less than US$5m (CA$1.8m revenue, or US$1.3m). Market cap is less than US$100m (€10.1m market cap, or US$11.0m).お知らせ • Aug 04Element Nutritional Sciences Inc. Rethinks Protein with Launch of Exclusive Patented PROMINO™ Brand Drink Mix and Ready-to-Drink BeveragesElement Nutritional Sciences Inc. is preparing the professional sports world for the launch of its PROMINO™ drink mix and ready-to-drink beverage by working closely with pro athletes in their "offices" – elite training facilities and locker rooms across the multiple pro sports leagues in North America. PROMINO™ is NSF Certified for sport, which means it is free of banned substances and approved by all major sports leagues. Additionally, Element invested in a rigorous flavoring process with a top tier U.S. flavor house responsible for creating the taste of several of North America's best-selling sports nutrition beverages. Followed by extensive in-market consumer testing, the Company will launch two refreshing fruit flavors in fourth quarter of 2023. In addition to great taste, PROMINO™ delivers: Less than 15 calories per serving; No fat, no sugar, no dairy; 100% plant-based formula and Increases muscle protein synthesis by 76%, more than two times the 35% delivered by whey protein. PROMINO's patented amino acid formula contains the essential building blocks of protein and are shown to be the higher quality protein source in the world based on the rising gold standard of protein quality – DIAAS – which measures the uptake of these key amino acids in the gut. With a 321 DIAAS (Digestible Indispensable Amino Acid Score), PROMINO™ is superior to whey protein at 133. PROMINO™ is more effective than whey protein at producing the desired results – with none of the fat, sugar, carbs and bloat. It is a significant step forward for pro and collegiate athletes.お知らせ • Jul 15Element Nutritional Sciences Inc. announced that it has received CAD 1.9065 million in fundingOn July 14, 2023, Element Nutritional Sciences Inc. closed the transaction. The company has amended the terms of the transaction. The company received CAD 780,000 in its second and final tranche. The company has received CAD 1,906,500 in the transaction. The Company paid finder’s fees in the aggregate amount of CAD 17,000 to certain arm’s-length parties who introduced purchasers to the Company.New Risk • Jun 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$3.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.7m free cash flow). Share price has been highly volatile over the past 3 months (27% average weekly change). Negative equity (-CA$5.6m). Earnings have declined by 24% per year over the past 5 years. Minor Risks Revenue is less than US$5m (CA$1.8m revenue, or US$1.4m). Market cap is less than US$100m (€14.1m market cap, or US$15.5m).Reported Earnings • Jun 17Full year 2022 earnings released: CA$0.097 loss per share (vs CA$0.10 loss in FY 2021)Full year 2022 results: CA$0.097 loss per share. Revenue: CA$4.00m (up 70% from FY 2021). Net loss: CA$10.3m (loss widened 18% from FY 2021).お知らせ • Jun 13+ 2 more updatesElement Nutritional Sciences' Announces Loblaws to Launch RejuvenateTM Muscle ActivatorElement Nutritional Sciences Inc. announced that it has received approval from Loblaws Supermarket ("Loblaws") to list its patented RejuvenateTM Muscle Activator in 150 stores, representing 300 points of distribution. Element expects that the listing could take place as soon as September 2023.お知らせ • Jun 08Element Nutritional Sciences' Rejuvenate™ Muscle Activator Scores Ahead of Popular Protein Sources in Protein Quality MeasurementElement Nutritional Sciences Inc. announced that its patented Rejuvenate™ Muscle Activator has recorded a score of 321 on the digestible indispensable amino acid score ("DIAAS"), a new and innovative protein quality measurement score recommended by the Food and Agriculture Organization. Rejuvenate™ Muscle Activator's score of 321 compares to a score of 1332 for whey protein (141% higher), 912 for soy protein (252% higher) and 822 for pea protein (291% higher). The market for protein-based beverages is large, with the whey protein market alone currently estimated to be $5.3 billion and expected to increase to over $11.2 billion by 20303. The DIAAS score accounts for the digestibility of amino acids absorbed by the body and the protein's contribution to human amino acid requirements. Rejuvenate™ Muscle Activator is composed of plant-based materials that are considered to be more digestible as it relates to calculating the DIAAS score.お知らせ • Jan 17Element Nutritional Sciences' RejuvenateTM Muscle Activator Now on Shelves at Shoppers Drug Mart and LoblawsElement Nutritional Sciences Inc. announced that the company's RejuvenateTM Muscle Activator stick packs are now on shelves at 700 Shoppers Drug Mart and Loblaws locations in Canada, adding 1,269 points of distribution for the company and bringing total points of distribution in North America to 33,000.お知らせ • Dec 26Element Nutritional Sciences Inc., Annual General Meeting, Feb 21, 2023Element Nutritional Sciences Inc., Annual General Meeting, Feb 21, 2023.Reported Earnings • Dec 01Third quarter 2022 earnings released: CA$0.023 loss per share (vs CA$0.031 loss in 3Q 2021)Third quarter 2022 results: CA$0.023 loss per share (improved from CA$0.031 loss in 3Q 2021). Revenue: CA$569.5k (down 11% from 3Q 2021). Net loss: CA$2.59m (loss narrowed 14% from 3Q 2021).Board Change • Nov 16High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 2 experienced directors. No highly experienced directors. CFO, Corporate Secretary & Director Shaun Power is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Sep 01Second quarter 2022 earnings released: CA$0.016 loss per share (vs CA$0.038 loss in 2Q 2021)Second quarter 2022 results: CA$0.016 loss per share (up from CA$0.038 loss in 2Q 2021). Revenue: CA$1.28m (up 19% from 2Q 2021). Net loss: CA$1.75m (loss narrowed 43% from 2Q 2021).Reported Earnings • Aug 01First quarter 2022 earnings released: CA$0.011 loss per share (vs CA$0.023 loss in 1Q 2021)First quarter 2022 results: CA$0.011 loss per share (up from CA$0.023 loss in 1Q 2021). Revenue: CA$2.28m (up CA$1.93m from 1Q 2021). Net loss: CA$1.11m (loss narrowed 23% from 1Q 2021).Board Change • Apr 27High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 2 experienced directors. No highly experienced directors. CFO, Corporate Secretary & Director Shaun Power is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Dec 02Third quarter 2020 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2020 results: CA$0.23 loss per share (down from CA$0.032 loss in 3Q 2019). Revenue: CA$182.5k (down 45% from 3Q 2019). Net loss: CA$4.62m (loss widened CA$3.97m from 3Q 2019). Revenue was in line with analyst estimates.Board Change • Sep 15Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). CFO, Corporate Secretary & Director Shaun Power is the most experienced director on the board, commencing their role in 2020. Independent Director Lino Fera was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Sep 10Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). CFO, Corporate Secretary & Director Shaun Power is the most experienced director on the board, commencing their role in 2020. Independent Director Lino Fera was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Sep 07Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). CFO, Corporate Secretary & Director Shaun Power is the most experienced director on the board, commencing their role in 2020. Independent Director Lino Fera was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Sep 01Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). CFO, Corporate Secretary & Director Shaun Power is the most experienced director on the board, commencing their role in 2020. Independent Director Lino Fera was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.株主還元93XDE Personal ProductsDE 市場7D55.0%3.0%0.7%1Yn/a-9.1%2.0%株主還元を見る業界別リターン: 93XがGerman Personal Products業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: 93X German市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is 93X's price volatile compared to industry and market?93X volatility93X Average Weekly Movement44.0%Personal Products Industry Average Movement5.1%Market Average Movement6.1%10% most volatile stocks in DE Market13.2%10% least volatile stocks in DE Market2.7%安定した株価: 93Xの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間の93Xのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2014n/aVito Sanzonedrinkpromino.com栄養補助食品会社であるプロミノ・ニュートリショナル・サイエンシズ社は、カナダと米国で栄養製品の開発に従事している。同社は、加齢やその他の病状により自然に失われる筋肉量の再構築、回復、若返りをサポートする独自の製剤「リジュブネイト」や、プロとアマチュアの両方のアスリート向けに、筋肉の回復を促進し、力をつけ、怪我からの回復を早めるプロテインパウダーやその他の栄養補助食品を「プロミノ」「JAKTRX」ブランドで提供している。また、店舗やオンラインを通じて製品の小売りも行っている。同社は以前Element Nutritional Sciences Inc.として知られていたが、2024年1月に社名をPromino Nutritional Sciences Inc.に変更した。Promino Nutritional Sciences Inc.は2014年に設立され、カナダのバーリントンを拠点としている。もっと見るPromino Nutritional Sciences Inc. 基礎のまとめPromino Nutritional Sciences の収益と売上を時価総額と比較するとどうか。93X 基礎統計学時価総額€5.82m収益（TTM）-€1.78m売上高(TTM)€1.28m4.6xP/Sレシオ-3.3xPER（株価収益率93X は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計93X 損益計算書（TTM）収益CA$2.05m売上原価CA$1.74m売上総利益CA$316.53kその他の費用CA$3.18m収益-CA$2.87m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.014グロス・マージン15.42%純利益率-139.69%有利子負債／自己資本比率-27.9%93X の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/31 03:35終値2026/05/29 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Promino Nutritional Sciences Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 31First quarter 2026 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 1Q 2025)First quarter 2026 results: CA$0.002 loss per share (improved from CA$0.005 loss in 1Q 2025). Revenue: CA$160.7k (down 38% from 1Q 2025). Net loss: CA$409.4k (loss narrowed 24% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.
お知らせ • May 22Promino Nutritional Sciences Inc. announced that it has received CAD 0.95931 million in fundingOn May 21, 2026, Promino Nutritional Sciences Inc. closed the transaction. The company issued 3,000,000 units at a price of CAD 0.03 per Unit for gross proceeds of CAD 90,000 in its final tranche. In aggregate, the Company issued 31,976,999 Units for gross proceeds of CAD 959,309.97 in its private placement. The Units are composed of one Share and one half of one Share purchase warrant, each whole warrant exercisable into one additional Share at a price of CAD 0.06 for one year from the date of issuance. All securities issued upon closing of the Final Tranche are subject to a four-month hold period in accordance with applicable securities laws.
お知らせ • Apr 11Promino Nutritional Sciences Inc. Launches NCAA Division I Athlete Platform Through Multi-Sport Nil Partnership with Virginia Military InstitutePromino Nutritional Sciences Inc. announced a multi-sport Name, Image and Likeness ("NIL") partnership with eight NCAA Division I student-athletes at the Virginia Military Institute ("VMI"). This agreement marks the formal launch of the Promino NCAA Athlete Platform, a strategic initiative designed to provide collegiate athletes with the Company's NSF Certified for Sport® proprietary amino acid formulations. The partnership includes eight cadet-athletes across VMI's Division I programs, who will integrate the formulation into their training and recovery protocols. The Company intends to utilize this multi-sport program as a model for potential expansion into additional NCAA athletic programs, subject to future agreements. Promino's performance platform is engineered to support muscle protein synthesis and recovery through precise, low-calorie formulations. Unlike traditional protein formats that require lengthy digestion, Promino's proprietary ratio is designed for rapid absorption, delivering muscle-building support without "digestive drag" or excess calories. Its core product, Rejuvenate Muscle Health™, is a clinically researched proprietary amino acid formula designed to rebuild, restore, and rejuvenate muscle tissue. The Company also produces Promino™ - NSF Certified for Sport®.
お知らせ • Mar 14Promino Nutritional Sciences Inc. announced that it expects to receive CAD 1.2 million in fundingPromino Nutritional Sciences Inc announced a non brokered private placement to issue 40,000,000 units of the Company ("Units") at a price of CAD 0.03 per Unit for gross proceeds of CAD 1,200,000 on March 13, 2026. Each Unit will consist of one common share and one half of one common share purchase warrant with each Warrant being exercisable to purchase one additional Share at a price of CAD 0.06 for twelve months from the date of issuance. The Company may pay finders' fees in connection with the Offering, as permitted by applicable securities laws and the rules of the Canadian Securities Exchange. The Offering is expected to close on or about April 15, 2026 and is subject to execution of subscription agreements by the placees and to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange. All securities issued in connection with the Offering will be subject to a four month and one day statutory resale restriction pursuant to applicable Canadian securities laws.
お知らせ • Dec 19Promino Nutritional Sciences Inc. announced that it expects to receive CAD 1.5 million in fundingPromino Nutritional Sciences Inc announced a non-brokered private placement to issue 50,000,000 units at an issue price of CAD 0.02 for the proceeds of CAD 1,000,000 on December 18, 2025. The company may increase the size of the new offering by up to 25,000,000 additional units. Each unit will consist of one common share and one common share purchase warrant, with each warrant being exercisable to purchase one additional share at a price of CAD 0.06 for 12 months from the date of issuance. The new offering is expected to close on or about January 30, 2026, and is subject to conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange. All securities issued in connection with the new offering will be subject to a four-month-and-one-day statutory resale restriction pursuant to applicable Canadian securities laws. On the same day the company amended the terms of the transaction. The company will now issue 50,000,000 units at an issue price of CAD 0.03 for gross proceeds of CAD 1,500,000. All other offering terms remain unchanged.
お知らせ • Dec 10Promino Nutritional Sciences Inc., Annual General Meeting, Feb 12, 2026Promino Nutritional Sciences Inc., Annual General Meeting, Feb 12, 2026.
Reported Earnings • May 31First quarter 2026 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 1Q 2025)First quarter 2026 results: CA$0.002 loss per share (improved from CA$0.005 loss in 1Q 2025). Revenue: CA$160.7k (down 38% from 1Q 2025). Net loss: CA$409.4k (loss narrowed 24% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.
お知らせ • May 22Promino Nutritional Sciences Inc. announced that it has received CAD 0.95931 million in fundingOn May 21, 2026, Promino Nutritional Sciences Inc. closed the transaction. The company issued 3,000,000 units at a price of CAD 0.03 per Unit for gross proceeds of CAD 90,000 in its final tranche. In aggregate, the Company issued 31,976,999 Units for gross proceeds of CAD 959,309.97 in its private placement. The Units are composed of one Share and one half of one Share purchase warrant, each whole warrant exercisable into one additional Share at a price of CAD 0.06 for one year from the date of issuance. All securities issued upon closing of the Final Tranche are subject to a four-month hold period in accordance with applicable securities laws.
お知らせ • Apr 11Promino Nutritional Sciences Inc. Launches NCAA Division I Athlete Platform Through Multi-Sport Nil Partnership with Virginia Military InstitutePromino Nutritional Sciences Inc. announced a multi-sport Name, Image and Likeness ("NIL") partnership with eight NCAA Division I student-athletes at the Virginia Military Institute ("VMI"). This agreement marks the formal launch of the Promino NCAA Athlete Platform, a strategic initiative designed to provide collegiate athletes with the Company's NSF Certified for Sport® proprietary amino acid formulations. The partnership includes eight cadet-athletes across VMI's Division I programs, who will integrate the formulation into their training and recovery protocols. The Company intends to utilize this multi-sport program as a model for potential expansion into additional NCAA athletic programs, subject to future agreements. Promino's performance platform is engineered to support muscle protein synthesis and recovery through precise, low-calorie formulations. Unlike traditional protein formats that require lengthy digestion, Promino's proprietary ratio is designed for rapid absorption, delivering muscle-building support without "digestive drag" or excess calories. Its core product, Rejuvenate Muscle Health™, is a clinically researched proprietary amino acid formula designed to rebuild, restore, and rejuvenate muscle tissue. The Company also produces Promino™ - NSF Certified for Sport®.
お知らせ • Mar 14Promino Nutritional Sciences Inc. announced that it expects to receive CAD 1.2 million in fundingPromino Nutritional Sciences Inc announced a non brokered private placement to issue 40,000,000 units of the Company ("Units") at a price of CAD 0.03 per Unit for gross proceeds of CAD 1,200,000 on March 13, 2026. Each Unit will consist of one common share and one half of one common share purchase warrant with each Warrant being exercisable to purchase one additional Share at a price of CAD 0.06 for twelve months from the date of issuance. The Company may pay finders' fees in connection with the Offering, as permitted by applicable securities laws and the rules of the Canadian Securities Exchange. The Offering is expected to close on or about April 15, 2026 and is subject to execution of subscription agreements by the placees and to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange. All securities issued in connection with the Offering will be subject to a four month and one day statutory resale restriction pursuant to applicable Canadian securities laws.
お知らせ • Dec 19Promino Nutritional Sciences Inc. announced that it expects to receive CAD 1.5 million in fundingPromino Nutritional Sciences Inc announced a non-brokered private placement to issue 50,000,000 units at an issue price of CAD 0.02 for the proceeds of CAD 1,000,000 on December 18, 2025. The company may increase the size of the new offering by up to 25,000,000 additional units. Each unit will consist of one common share and one common share purchase warrant, with each warrant being exercisable to purchase one additional share at a price of CAD 0.06 for 12 months from the date of issuance. The new offering is expected to close on or about January 30, 2026, and is subject to conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange. All securities issued in connection with the new offering will be subject to a four-month-and-one-day statutory resale restriction pursuant to applicable Canadian securities laws. On the same day the company amended the terms of the transaction. The company will now issue 50,000,000 units at an issue price of CAD 0.03 for gross proceeds of CAD 1,500,000. All other offering terms remain unchanged.
お知らせ • Dec 10Promino Nutritional Sciences Inc., Annual General Meeting, Feb 12, 2026Promino Nutritional Sciences Inc., Annual General Meeting, Feb 12, 2026.
お知らせ • Dec 09Promino Nutritional Sciences Inc. announced that it expects to receive CAD 1 million in fundingPromino Nutritional Sciences Inc. announced non-brokered private placement of 15% secured convertible debentures due December 3, 2028 for an aggregate principal amount of up to CAD 1,000,000 on December 9, 2025. The Company may increase the size of the Offering by up to an additional CAD 500,000 of Convertible Debentures for aggregate gross proceeds of up to CAD 1,500,000. Each Convertible Debenture will consist of a CAD 1,000 principal amount and be secured against company's present and after-acquired inventory. The Convertible Debentures will bear interest at a rate of 15% per annum, payable quarterly in, at the election of the company, cash or common shares of the Company at a conversion price of the greater of (i) CAD 0.05 and (ii) the five-day VWAP of the Shares prior to the interest payment date. The principal amount outstanding under the Convertible Debentures will be, at the election of the company, payable in cash or convertible into Shares at a conversion price of CAD 0.05 per Share on maturity three (3) years from the date of issuance (the "Maturity Date"). The company may also elect to repay the principal amount of the Convertible Debentures in cash, in whole or in part, at any time prior to the Maturity Date. The Convertible Debentures shall be convertible at the option of the holder, in whole or in part, and at any time prior to the Maturity Date, into Shares at a conversion price of CAD 0.05 per Share. The Offering is subject to the approval of the Canadian Securities Exchange ("CSE"). The Convertible Debentures and the Shares issuable upon conversion of the Convertible Debentures or any interest thereon will be subject to a four month and one day statutory resale restriction pursuant to applicable Canadian securities laws. The Offering is expected to close on or about January 30, 2026 and is subject to execution of subscription agreements by the placees and to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the CSE. The company also announces that it has granted 500,000 options to purchase Shares, with an exercise price of CAD 0.05 and maturity date of December 3, 2028, to a consultant of the Company. The securities issued under this grant are subject to a four month and one day statutory resale restriction pursuant to applicable Canadian securities laws.
お知らせ • Sep 08+ 1 more updatePromino Nutritional Sciences Inc. Announces Management ChangesPromino Nutritional Sciences Inc. announced that Moira Ong has been appointed as Corporate Secretary and Vito Sanzone has been appointed as a Director of the Company. Mr. Sanzone is currently the CEO. Mr. Sanzone has 25 years of experience in the health, wellness and fitness industry and has had executive roles in three performance nutrition mergers and acquisitions worth a combined $1 billion. Ms. Ong has over 20 years' experience in financial reporting, compliance and audit. Ms. Ong has served as Vice President of Finance and Chief Financial Officer of private and publicly-listed entities since 2010 and assisted these companies with public listings processes, mergers and acquisitions. The Company also announces that Shaun Power has resigned as Corporate Secretary and Director. The Company wishes to thank Mr. Power for his contributions to the Company.
お知らせ • Apr 04Promino Nutritional Sciences Inc. announced that it has received CAD 0.86405 million in fundingOn April 3, 2025, Promino Nutritional Sciences Inc closed the transaction. The company issued 10,881,000 Units at a price of CAD 0.05 per Unit for gross proceeds of CAD 544,050. The company paid cash finder's fees in the aggregate amount of CAD 35,073.50 and issued an aggregate of 701,470 non-transferable finder's unit warrants.
お知らせ • Sep 18Promino Nutritional Sciences Inc. Begins Preclinical Trial to Demonstrate Effectiveness of Promino™ Patented IP for Retention of Muscle Mass in Cancer Patients Undergoing Aggressive Chemotherapy TreatmentPromino Nutritional Sciences Inc. has announced the commencement of the preclinical trial to demonstrate the effectiveness of the Promino™ patented IP for the retention of muscle mass in cancer patients undergoing aggressive chemotherapy treatment. The preclinical trial will be led by Dr. Patrick Gunning, who was appointed as special advisor to the Company on May 8, 2024 to conduct these trials. Results of the preclinical trials are expected in 10 weeks. If testing affirms the effectiveness of the patented IP in retaining muscle mass in chemotherapy patients, the Company will likely develop a specialized formulation specifically for marketing to the practitioner channel in North America.
お知らせ • Sep 09Promino Nutritional Sciences Inc. Announces the Release of Results of A New Human Clinical TrialPromino Nutritional Sciences Inc. announced the release of results of a new human clinical trial led by Dr. Robert R. Wolfe, Phd. The trial found that a 3.6 gram serving of Rejuvenate Muscle ActivatorTM has the same effect on muscle protein synthesis as 40 grams of whey protein. The clinical trial measured protein equivalency between the patented essential amino acid blend underlying Rejuvenate Muscle ActivatorTM and ProminoTM versus traditional whey protein, long considered the leader in muscle health. The patented amino acid blend was found to be 11x more effective than whey protein isolate gram-for-gram. Research from Dr. Wolfe and his team at the University of Arkansas can be found here. Promino is the exclusive licensor of the patent for the global mass consumer and sports nutrition markets. The patent is the result of over 20 years of research, over 25 clinical trials and funding of over USD 20 million. The Company recently re-launched Rejuvenate Muscle ActivatorTM (3.6 gram serving), marketed to the mass active nutrition and wellness category, and ProminoTM- NSF Certified for Sport® (11 gram serving), designed for professional and collegiate athletes and sports nutrition channels. The results of the clinical trial demonstrate the commercial value of the patented blend by supporting its efficiency, cost effectiveness and clean formula.
Reported Earnings • Sep 05Second quarter 2024 earnings released: CA$0.042 loss per share (vs CA$0.028 loss in 2Q 2023)Second quarter 2024 results: CA$0.042 loss per share (further deteriorated from CA$0.028 loss in 2Q 2023). Revenue: CA$11.6k (down 90% from 2Q 2023). Net loss: CA$2.72m (loss widened 161% from 2Q 2023).
お知らせ • Jul 10Promino Nutritional Sciences Inc. announced that it has received CAD 1.749001 million in fundingOn July 9, 2024, Promino Nutritional Sciences Inc. closed the transaction. The company issued 166,666 Units at a price of CAD 0.18 per Unit for gross proceeds of CAD 29,999.88 in second and final tranche. Each Unit comprised of one common share and one common share purchase warrant. Each warrant is exercisable to acquire one common share of the Company at a price of CAD 0.30 per share for a period of 24 months from the date of issuance. Together with the first tranche, the Company has issued an aggregate of 9,716,671 Units for gross proceeds of CAD 1,749,000.78. All securities issued in connection with the second tranche are subject to a hold period of four months and one day pursuant to applicable securities laws. The Company did not pay any finder’s fees, in cash nor securities, in connection with the second tranche.
お知らせ • May 15Promino Nutritional Sciences Inc., Annual General Meeting, Jul 09, 2024Promino Nutritional Sciences Inc., Annual General Meeting, Jul 09, 2024. Location: british columbia, vancouver Canada
Reported Earnings • May 09Full year 2023 earnings released: CA$0.15 loss per share (vs CA$0.29 loss in FY 2022)Full year 2023 results: CA$0.15 loss per share (improved from CA$0.29 loss in FY 2022). Revenue: CA$478.2k (down 88% from FY 2022). Net loss: CA$5.81m (loss narrowed 44% from FY 2022).
お知らせ • Apr 30Promino Nutritional Sciences Inc. (CNSX:MUSL) entered into a binding letter of intent to acquire Helios Helium Corp. for CAD 5.84 million.Promino Nutritional Sciences Inc. (CNSX:MUSL) entered into a binding letter of intent to acquire Helios Helium Corp. for CAD 5.84 million on April 29, 2024. Total share consideration is expected to be approximately 36.5 million Promino common shares. Pursuant to the LOI, Helios will spin out its helium property and sundry assets into a new entity, such that Helios’ assets will only be comprised of cash and certain marketable securities. Thereafter, each shareholder of Helios will receive one common share of the Company in exchange for each common share of Helios held. Completion of the Transaction will be subject to the satisfaction or waiver of customary conditions, including the satisfactory completion of due diligence, the entering into of a definitive agreement for the proposed Transaction and the receipt of all necessary approvals and consents, including regulatory, corporate, court and shareholder approval, if applicable.
New Risk • Feb 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 52% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (37% average weekly change). Negative equity (-CA$7.7m). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (52% increase in shares outstanding). Revenue is less than US$1m (CA$265k revenue, or US$197k). Minor Risk Market cap is less than US$100m (€10.1m market cap, or US$10.8m).
お知らせ • Feb 07Promino Nutritional Sciences Inc. announced that it has received CAD 2.208075 million in fundingOn February 6, 2024, Promino Nutritional Sciences Inc. closed the transaction. The company issued 44,161,500 units at an issue price of CAD 0.05 for the gross proceeds of up to CAD 2,208,075. Each unit will be comprised of one common share of the company and one-half of one common share purchase warrant, with each whole warrant exercisable to acquire one common share of the company at a price of CAD 0.10 per share for a period of 24 months from the date of issuance. All securities issued in connection with the offering will be subject to a statutory hold period of four months and one day. The company paid cash finder's fees in the aggregate amount of CAD 113,570 and issued2,271,400 finder's warrants to certain finders who introduced purchasers to the Company. Each finder's warrant is exercisable to acquire one common share of the Company at a price of CAD 0.10 per share for a period of 24 months from the date of issuance. The transaction included participation from an insider of the Company for 1,000,000 Units.
New Risk • Nov 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$2.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.1m free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Negative equity (-CA$7.7m). Earnings have declined by 18% per year over the past 5 years. Revenue is less than US$1m (CA$265k revenue, or US$195k). Market cap is less than US$10m (€3.22m market cap, or US$3.51m). Minor Risk Shareholders have been diluted in the past year (6.4% increase in shares outstanding).
お知らせ • Oct 12Element Nutritional Sciences Inc. Appoints Adam Berk as AdvisorElement Nutritional Sciences Inc. announced the appointment of Adam Berk as an independent Advisor to aid the Company to accelerate commercialization of its RejuvenateTM and PROMINO TM brands. Most recently, Mr. Berk was President of a renowned nutraceutical and vitamin company where he aided in acquisitions and helped grow the brand. Mr. Berk's most notable experience also includes over five years as Chairman and CEO of Stem Holdings Inc., three years as CEO of HYD for Men, and Co-CEO of Osmio, LLC.
お知らせ • Sep 27+ 1 more updateElement Nutritional Sciences Inc. Announces Executive ChangesElement Nutritional Sciences Inc. named veteran health and fitness executive Vito Sanzone as Chief Executive Officer, replacing founder Stuart Lowther who resigned as Chief Executive Officer to address personal matters. The change is effective immediately. Mr. Sanzone previously served Element as Chief Marketing Officer and has helped drive the creation of Element's new product portfolio. He has been part of over USD 1 billion in mergers and acquisitions in the health and active nutrition industry since 2016. Prior to Element, Mr. Sanzone was Chief Executive Officer of Complete Nutrition, Inc, where he spearheaded the transition to a major digital presence. As President of Maximum Human Performance, he repositioned the brand for sale in 2017. He also served as a key executive of Iovate Health Sciences in Oakville, Ontario from 2007 to 2016.
New Risk • Aug 27New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-CA$5.6m). Earnings have declined by 24% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Revenue is less than US$5m (CA$1.8m revenue, or US$1.3m). Market cap is less than US$100m (€10.1m market cap, or US$11.0m).
お知らせ • Aug 04Element Nutritional Sciences Inc. Rethinks Protein with Launch of Exclusive Patented PROMINO™ Brand Drink Mix and Ready-to-Drink BeveragesElement Nutritional Sciences Inc. is preparing the professional sports world for the launch of its PROMINO™ drink mix and ready-to-drink beverage by working closely with pro athletes in their "offices" – elite training facilities and locker rooms across the multiple pro sports leagues in North America. PROMINO™ is NSF Certified for sport, which means it is free of banned substances and approved by all major sports leagues. Additionally, Element invested in a rigorous flavoring process with a top tier U.S. flavor house responsible for creating the taste of several of North America's best-selling sports nutrition beverages. Followed by extensive in-market consumer testing, the Company will launch two refreshing fruit flavors in fourth quarter of 2023. In addition to great taste, PROMINO™ delivers: Less than 15 calories per serving; No fat, no sugar, no dairy; 100% plant-based formula and Increases muscle protein synthesis by 76%, more than two times the 35% delivered by whey protein. PROMINO's patented amino acid formula contains the essential building blocks of protein and are shown to be the higher quality protein source in the world based on the rising gold standard of protein quality – DIAAS – which measures the uptake of these key amino acids in the gut. With a 321 DIAAS (Digestible Indispensable Amino Acid Score), PROMINO™ is superior to whey protein at 133. PROMINO™ is more effective than whey protein at producing the desired results – with none of the fat, sugar, carbs and bloat. It is a significant step forward for pro and collegiate athletes.
お知らせ • Jul 15Element Nutritional Sciences Inc. announced that it has received CAD 1.9065 million in fundingOn July 14, 2023, Element Nutritional Sciences Inc. closed the transaction. The company has amended the terms of the transaction. The company received CAD 780,000 in its second and final tranche. The company has received CAD 1,906,500 in the transaction. The Company paid finder’s fees in the aggregate amount of CAD 17,000 to certain arm’s-length parties who introduced purchasers to the Company.
New Risk • Jun 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$3.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.7m free cash flow). Share price has been highly volatile over the past 3 months (27% average weekly change). Negative equity (-CA$5.6m). Earnings have declined by 24% per year over the past 5 years. Minor Risks Revenue is less than US$5m (CA$1.8m revenue, or US$1.4m). Market cap is less than US$100m (€14.1m market cap, or US$15.5m).
Reported Earnings • Jun 17Full year 2022 earnings released: CA$0.097 loss per share (vs CA$0.10 loss in FY 2021)Full year 2022 results: CA$0.097 loss per share. Revenue: CA$4.00m (up 70% from FY 2021). Net loss: CA$10.3m (loss widened 18% from FY 2021).
お知らせ • Jun 13+ 2 more updatesElement Nutritional Sciences' Announces Loblaws to Launch RejuvenateTM Muscle ActivatorElement Nutritional Sciences Inc. announced that it has received approval from Loblaws Supermarket ("Loblaws") to list its patented RejuvenateTM Muscle Activator in 150 stores, representing 300 points of distribution. Element expects that the listing could take place as soon as September 2023.
お知らせ • Jun 08Element Nutritional Sciences' Rejuvenate™ Muscle Activator Scores Ahead of Popular Protein Sources in Protein Quality MeasurementElement Nutritional Sciences Inc. announced that its patented Rejuvenate™ Muscle Activator has recorded a score of 321 on the digestible indispensable amino acid score ("DIAAS"), a new and innovative protein quality measurement score recommended by the Food and Agriculture Organization. Rejuvenate™ Muscle Activator's score of 321 compares to a score of 1332 for whey protein (141% higher), 912 for soy protein (252% higher) and 822 for pea protein (291% higher). The market for protein-based beverages is large, with the whey protein market alone currently estimated to be $5.3 billion and expected to increase to over $11.2 billion by 20303. The DIAAS score accounts for the digestibility of amino acids absorbed by the body and the protein's contribution to human amino acid requirements. Rejuvenate™ Muscle Activator is composed of plant-based materials that are considered to be more digestible as it relates to calculating the DIAAS score.
お知らせ • Jan 17Element Nutritional Sciences' RejuvenateTM Muscle Activator Now on Shelves at Shoppers Drug Mart and LoblawsElement Nutritional Sciences Inc. announced that the company's RejuvenateTM Muscle Activator stick packs are now on shelves at 700 Shoppers Drug Mart and Loblaws locations in Canada, adding 1,269 points of distribution for the company and bringing total points of distribution in North America to 33,000.
お知らせ • Dec 26Element Nutritional Sciences Inc., Annual General Meeting, Feb 21, 2023Element Nutritional Sciences Inc., Annual General Meeting, Feb 21, 2023.
Reported Earnings • Dec 01Third quarter 2022 earnings released: CA$0.023 loss per share (vs CA$0.031 loss in 3Q 2021)Third quarter 2022 results: CA$0.023 loss per share (improved from CA$0.031 loss in 3Q 2021). Revenue: CA$569.5k (down 11% from 3Q 2021). Net loss: CA$2.59m (loss narrowed 14% from 3Q 2021).
Board Change • Nov 16High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 2 experienced directors. No highly experienced directors. CFO, Corporate Secretary & Director Shaun Power is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Sep 01Second quarter 2022 earnings released: CA$0.016 loss per share (vs CA$0.038 loss in 2Q 2021)Second quarter 2022 results: CA$0.016 loss per share (up from CA$0.038 loss in 2Q 2021). Revenue: CA$1.28m (up 19% from 2Q 2021). Net loss: CA$1.75m (loss narrowed 43% from 2Q 2021).
Reported Earnings • Aug 01First quarter 2022 earnings released: CA$0.011 loss per share (vs CA$0.023 loss in 1Q 2021)First quarter 2022 results: CA$0.011 loss per share (up from CA$0.023 loss in 1Q 2021). Revenue: CA$2.28m (up CA$1.93m from 1Q 2021). Net loss: CA$1.11m (loss narrowed 23% from 1Q 2021).
Board Change • Apr 27High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 2 experienced directors. No highly experienced directors. CFO, Corporate Secretary & Director Shaun Power is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Dec 02Third quarter 2020 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2020 results: CA$0.23 loss per share (down from CA$0.032 loss in 3Q 2019). Revenue: CA$182.5k (down 45% from 3Q 2019). Net loss: CA$4.62m (loss widened CA$3.97m from 3Q 2019). Revenue was in line with analyst estimates.
Board Change • Sep 15Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). CFO, Corporate Secretary & Director Shaun Power is the most experienced director on the board, commencing their role in 2020. Independent Director Lino Fera was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Sep 10Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). CFO, Corporate Secretary & Director Shaun Power is the most experienced director on the board, commencing their role in 2020. Independent Director Lino Fera was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Sep 07Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). CFO, Corporate Secretary & Director Shaun Power is the most experienced director on the board, commencing their role in 2020. Independent Director Lino Fera was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Sep 01Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). CFO, Corporate Secretary & Director Shaun Power is the most experienced director on the board, commencing their role in 2020. Independent Director Lino Fera was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
